Advanced

Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder

Johansson, J-E; Remberger, M.; Lazarevic, Vladimir LU ; Hallbook, H.; Wahlin, A.; Kimby, E.; Juliusson, Gunnar LU ; Omar, H. and Hagglund, H. (2011) In Bone Marrow Transplantation 46(6). p.870-875
Abstract
Allogeneic transplantation after reduced intensity conditioning (allo-RIC) is a treatment option for patients with Hodgkin's lymphoma (HL) relapsing after autologous transplantation. In all, 23 adult patients with HL underwent allo-RIC in Sweden between 2000 and 2007. The median number of previous treatment lines was five and 20 patients (87%) were previously autografted. TRM at 100 days and at 1 year was 13 and 22% respectively. Acute GVHD grades II-IV developed in 7 out of 23 patients (30%) and chronic GVHD in 10 out of 20 patients at risk (50%). The OS and EFS at three years was 59 and 27%, respectively. Four patients (17%) developed post transplant lymphoproliferative disease (PTLD) after a median time of 55 days (range 38-95); two of... (More)
Allogeneic transplantation after reduced intensity conditioning (allo-RIC) is a treatment option for patients with Hodgkin's lymphoma (HL) relapsing after autologous transplantation. In all, 23 adult patients with HL underwent allo-RIC in Sweden between 2000 and 2007. The median number of previous treatment lines was five and 20 patients (87%) were previously autografted. TRM at 100 days and at 1 year was 13 and 22% respectively. Acute GVHD grades II-IV developed in 7 out of 23 patients (30%) and chronic GVHD in 10 out of 20 patients at risk (50%). The OS and EFS at three years was 59 and 27%, respectively. Four patients (17%) developed post transplant lymphoproliferative disease (PTLD) after a median time of 55 days (range 38-95); two of these patients later died. The study confirmed that allo-RIC is feasible, but associated with a substantial relapse rate: only 20% of the patients were still alive 7 years after the transplant. A finding of high incidence of PTLD needs to be confirmed in a larger trial that includes patients with non-HL and CLL. Bone Marrow Transplantation (2011) 46, 870-875; doi: 10.1038/bmt.2010.238; published online 18 October 2010 (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
allogeneic, transplantation, Hodgkin's lymphoma, post transplant, lymphoproliferative disorder, reduced intensity conditioning
in
Bone Marrow Transplantation
volume
46
issue
6
pages
870 - 875
publisher
Nature Publishing Group
external identifiers
  • wos:000291383100015
  • scopus:79958159262
ISSN
1476-5365
DOI
10.1038/bmt.2010.238
language
English
LU publication?
yes
id
dba179b9-4a49-4a73-bdaf-60b64b762470 (old id 1985604)
date added to LUP
2011-07-01 09:02:40
date last changed
2017-01-01 03:57:37
@article{dba179b9-4a49-4a73-bdaf-60b64b762470,
  abstract     = {Allogeneic transplantation after reduced intensity conditioning (allo-RIC) is a treatment option for patients with Hodgkin's lymphoma (HL) relapsing after autologous transplantation. In all, 23 adult patients with HL underwent allo-RIC in Sweden between 2000 and 2007. The median number of previous treatment lines was five and 20 patients (87%) were previously autografted. TRM at 100 days and at 1 year was 13 and 22% respectively. Acute GVHD grades II-IV developed in 7 out of 23 patients (30%) and chronic GVHD in 10 out of 20 patients at risk (50%). The OS and EFS at three years was 59 and 27%, respectively. Four patients (17%) developed post transplant lymphoproliferative disease (PTLD) after a median time of 55 days (range 38-95); two of these patients later died. The study confirmed that allo-RIC is feasible, but associated with a substantial relapse rate: only 20% of the patients were still alive 7 years after the transplant. A finding of high incidence of PTLD needs to be confirmed in a larger trial that includes patients with non-HL and CLL. Bone Marrow Transplantation (2011) 46, 870-875; doi: 10.1038/bmt.2010.238; published online 18 October 2010},
  author       = {Johansson, J-E and Remberger, M. and Lazarevic, Vladimir and Hallbook, H. and Wahlin, A. and Kimby, E. and Juliusson, Gunnar and Omar, H. and Hagglund, H.},
  issn         = {1476-5365},
  keyword      = {allogeneic,transplantation,Hodgkin's lymphoma,post transplant,lymphoproliferative disorder,reduced intensity conditioning},
  language     = {eng},
  number       = {6},
  pages        = {870--875},
  publisher    = {Nature Publishing Group},
  series       = {Bone Marrow Transplantation},
  title        = {Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder},
  url          = {http://dx.doi.org/10.1038/bmt.2010.238},
  volume       = {46},
  year         = {2011},
}